On March 2, 2023 Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of Akebia Therapeutics, Inc. (the "Company"), and Siegfried Evionnaz SA ("Siegfried") reported that it has entered into Amendment No. 5 to Master Manufacturing Services and Supply Agreement (the "Amendment"), which further amends the Master Manufacturing Services and Supply Agreement dated December 20, 2017 (as amended, the "Supply Agreement") (Filing, 8-K, Akebia, MAR 2, 2023, View Source [SID1234628046]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Amendment, the Company agreed to purchase a minimum quantity of drug substance for Auryxia at a predetermined price. As a result of the Amendment, the term of the Supply Agreement expires on December 31, 2024, subject to the Company’s option to extend through December 31, 2026 by providing 12 months’ prior written notice to Siegfried.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the three months ending March 31, 2023.